Chiron Capital Management LLC Reduces Stock Position in Gilead Sciences, Inc. $GILD

Key Points

• Chiron Capital Management LLC reduced its stake in Gilead Sciences by 54.4%, selling 12,451 shares to hold 10,423 shares, which now make up approximately 1.1% of its portfolio.
• In recent insider trading, Director Jeffrey Bluestone and CEO Daniel Patrick O'day sold 5,000 and 10,000 shares respectively, reflecting a decrease in their ownership stakes.
• The company announced a quarterly dividend of $0.79, set to be paid on September 29th, with a 2.8% dividend yield and a payout ratio of 62.95%.

Chiron Capital Management LLC cut its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 54.4% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 10,423 shares of the biopharmaceutical company's stock after selling 12,451 shares during the period. Gilead Sciences comprises about 1.1% of Chiron Capital Management LLC's holdings, making the stock its 25th largest holding. Chiron Capital Management LLC's holdings in Gilead Sciences were worth $1,168,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently bought and sold shares of the company. Redwood Financial Network Corp increased its stake in shares of Gilead Sciences by 4.0% during the fourth quarter. Redwood Financial Network Corp now owns 2,530 shares of the biopharmaceutical company's stock worth $234,000 after buying an additional 98 shares during the period. Argentarii LLC increased its position in shares of Gilead Sciences by 3.0% in the 1st quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company's stock valued at $380,000 after purchasing an additional 99 shares during the last quarter. Peak Financial Advisors LLC raised its holdings in shares of Gilead Sciences by 1.7% in the 1st quarter. Peak Financial Advisors LLC now owns 6,040 shares of the biopharmaceutical company's stock valued at $677,000 after purchasing an additional 100 shares in the last quarter. Perkins Coie Trust Co lifted its position in shares of Gilead Sciences by 2.6% during the 1st quarter. Perkins Coie Trust Co now owns 3,880 shares of the biopharmaceutical company's stock worth $435,000 after purchasing an additional 100 shares during the last quarter. Finally, Investment Research & Advisory Group Inc. grew its stake in shares of Gilead Sciences by 33.3% during the first quarter. Investment Research & Advisory Group Inc. now owns 400 shares of the biopharmaceutical company's stock worth $45,000 after purchasing an additional 100 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company's stock.

Gilead Sciences Price Performance

GILD stock traded up $2.28 during trading on Friday, reaching $115.05. 6,953,644 shares of the company were exchanged, compared to its average volume of 8,095,748. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The stock's 50 day moving average price is $113.50 and its 200 day moving average price is $109.82. Gilead Sciences, Inc. has a 52-week low of $78.26 and a 52-week high of $121.83. The company has a market cap of $142.76 billion, a P/E ratio of 22.92, a PEG ratio of 0.77 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. The company had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company's revenue for the quarter was up 1.4% on a year-over-year basis. During the same period last year, the firm earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Shareholders of record on Monday, September 15th will be issued a $0.79 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 annualized dividend and a yield of 2.7%. Gilead Sciences's dividend payout ratio is 62.95%.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Friday, August 15th. The stock was sold at an average price of $118.53, for a total transaction of $296,325.00. Following the completion of the transaction, the chief financial officer owned 160,110 shares of the company's stock, valued at $18,977,838.30. The trade was a 1.54% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $118.53, for a total transaction of $3,318,840.00. Following the completion of the sale, the insider directly owned 114,168 shares in the company, valued at approximately $13,532,333.04. The trade was a 19.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 82,000 shares of company stock worth $9,371,330. Corporate insiders own 0.27% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on GILD shares. Royal Bank Of Canada boosted their target price on Gilead Sciences from $96.00 to $98.00 and gave the stock a "sector perform" rating in a research note on Friday, August 8th. Truist Financial raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and raised their price objective for the stock from $108.00 to $127.00 in a report on Friday, August 8th. UBS Group upped their target price on shares of Gilead Sciences from $108.00 to $112.00 and gave the company a "neutral" rating in a report on Friday, August 8th. Needham & Company LLC upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price target on the stock in a research note on Friday, July 25th. Finally, Daiwa America upgraded shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, August 19th. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $115.39.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.